Paediatric vaginal discharge and precocious puberty

• In girls who have not started puberty, true vaginal bleeding or persistent discharge is always abnormal; only the scant, blood-tinged discharge of the first week of life is physiological.
• Most cases are benign: non-specific vulvovaginitis from irritants, poor hygiene or bacteria that belong to the skin and bowel, and a small swallowed or inserted foreign body.
• A small minority have a serious cause: an underlying tumour, traumatic injury, or abuse. Blood-stained discharge that does not settle needs investigation.
• Precocious puberty means the body's puberty starts before age 8 in girls. Central precocious puberty is driven by the brain; peripheral precocious puberty is driven by the ovaries, adrenal glands or medicines.
• Modern guidelines (Endocrine Society 2026; ESPE/LWPES consensus) suggest watching and waiting in many girls whose breast development starts at 7 to 8 years, imaging and treating only those who progress.

By the end of this page you should be able to:

1. List the causes of vaginal discharge and bleeding in prepubertal girls and rank them by urgency.
2. Take a focused history and examine a prepubertal girl without causing distress or harm.
3. Work through investigations in the right order, from swab to imaging to examination under anaesthesia.
4. Tell central from peripheral precocious puberty, and plan the correct work-up and treatment.
5. Recognise red flags, handle suspected abuse and low-resource settings, and avoid common traps.

This page is about two presentations that overlap in clinical practice: vaginal discharge or bleeding in a prepubertal girl, and early puberty in a girl. A blood-stained discharge can be the first visible sign of precocious puberty when oestrogen has begun to stimulate the uterus; conversely, asking whether early breast development is present is part of assessing any bleed in a girl who is not yet menstruating.

Prepubertal means the child has not yet entered puberty: no pubic or axillary hair, no breast development, no menarche. In this state the vagina is narrow, un-estrogenised and has a thin epithelium with an alkaline pH. That single fact explains why vulvovaginitis is so common in young girls and why internal examination in the clinic is impossible.

The page follows the presentation outline: causes first, then red flags, history, examination, investigations, algorithm, immediate and definitive management, special groups, traps and linkage.

A useful way to think about causes is to group them by what drives the discharge or bleed. A single child can have more than one (for example, a foreign body with overlaying vulvovaginitis and secondary infection).

Because vulvovaginitis is so common, it deserves the most attention. A large BMJ review from 2005 summarised the agreed picture well.^[2]

• Aetiology. The hypo-oestrogenic state makes the mucosa thin, uncornified and alkaline. Other risk factors are the close proximity of the rectum, the lack of labial fat pads and pubic hair, small labia minora, poor local hygiene, spread of respiratory bacteria by hand-to-perineum contact, and local irritants such as bubble baths and tight clothing.^[2]
• Microbiology. In 25 to 75% of cases, no specific pathogen is isolated, because ordinary skin and bowel flora are cultured.^[2] Mixed anaerobes and common aerobes are often found in both symptomatic and asymptomatic girls. Pure or predominant growth of a true pathogen matters more than simply finding an organism.^[2] Haemophilus influenzae and group A beta-haemolytic streptococcus are regarded as pathogenic in this age group; Shigella and Enterobius vermicularis are less common but recognisable. Candida is unusual unless there is recent antibiotic use, diabetes or nappy use. Organisms associated with sexual transmission (Neisseria gonorrhoeae, Chlamydia trachomatis) should prompt a careful evaluation for abuse.^[2]
• Clinical features. Discharge occurs in 62 to 92% of cases, redness in 82%, soreness in 74%, itching in 45 to 58%, dysuria in 19% and bleeding in 5 to 10%.^[2] The discharge is often white or grey, sometimes mucoid or slightly blood-streaked, and may have a noticeable odour. Symptoms worsen after irritants (bubble baths, swimming pools) and towards the end of the day.
• Management. For non-specific vulvovaginitis, management is hygiene advice, sitz baths and barrier creams; antibiotics are reserved for a pure or predominant growth of a recognised pathogen.^[2] Threadworm infestation is treated with an anthelmintic according to local formulary. Candida, if confirmed, is treated topically, but empiric antifungals have no place in initial care.^[2] If symptoms are recurrent or persistent, the child should be referred to rule out a foreign body.^[2]

A foreign body is one of the most important causes to exclude because it is common, fixable, and can be missed for months. In the Australian vaginoscopy series of prepubertal girls, a foreign body was found in 12.7% of those presenting with bleeding and 20.6% of those presenting with discharge; vulvovaginitis was present in 7.0% and 20.6% respectively.^[1] Small organic material (hair, toilet paper, nappy padding) was the commonest type.^[1]

Trauma may be accidental (straddle injury, bike handlebar) or inflicted. It includes posterior hymenal or introital tears, vaginal wall lacerations and perineal tears, and can present with a small amount of bright bleeding. Any trauma should trigger a safeguarding assessment, and genital findings must be interpreted only by a clinician trained in paediatric forensic examination.

Genital tract malignancy is rare in children (less than 5% of all malignancies in children), but prepubertal bleeding is abnormal until proven otherwise. In the Australian series, malignancy accounted for 2 of 120 vaginoscopies (1.7%) and occurred only in children who bled; both had a visible mass at the introitus and both were rhabdomyosarcoma and endodermal sinus tumour.^[1] Benign Mullerian papilloma occurred in 5 of 86 (5.8%).^[1]

Lichen sclerosus presents with pale, figure-of-eight, atrophic skin that splits and bleeds, often with constipation and dysuria; it can be mistaken for abuse. Diagnosis is clinical but biopsy may be needed.

In girls, precocious puberty is conventionally defined as the onset of secondary sexual characteristics before age 8, and in boys before age 9.^[3] Precocious puberty is classified as central or peripheral.

• Central (GnRH-dependent) precocious puberty results from premature activation of the hypothalamic-pituitary-gonadal axis. It is much more common in girls, and is usually idiopathic. Organic causes include hypothalamic hamartoma, brain tumours, hydrocephalus, CNS infection and radiotherapy.
• Peripheral (GnRH-independent) precocious puberty results from oestrogen exposure from the ovaries, adrenals, external sources or autonomous secretion, without activation of the pubertal axis.

Causes of peripheral puberty in girls include ovarian cysts or tumours (granulosa theca cell tumour), McCune-Albright syndrome (café-au-lait patches, polyostotic bone lesions, autonomous ovarian cysts), congenital adrenal hyperplasia, adrenal tumours, hypothyroidism (van Wyk-Grumbach syndrome, with delayed bone age and multicystic ovaries), and exogenous sex steroids from creams, medicines or environmental exposure. These children have suppressed gonadotrophins on basal or GnRH testing, even though oestradiol is high.

List these mentally (and in the safety brief) for every girl with bleeding or discharge:

• Bleeding at any age before menarche, other than the neonatal first week.
• Persistent or recurrent discharge despite initial conservative care (a retained foreign body or another structural cause must be considered).
• Blood-stained, foul or unilateral discharge strongly suggesting a retained object.
• Any suspicion of sexual abuse, including genital injury, STI-pathogen growth, developmentally inappropriate sexual behaviour, or a disclosure.
• Genital mass, rapidly enlarging breast development, or signs of virilisation (clitoromegaly, deep voice, acne, accelerated growth).
• Systemic symptoms: fever, weight loss, pallor, bone pain, or neurological symptoms (headache, visual changes, seizures).
• A girl who is unable to tolerate examination, or whose history and examination do not fit together.
• Failure to respond to straightforward treatment.

A particularly alarming pair is genital bleeding with a mass in a toddler: present urgently to paediatric oncology/surgery teams and do not wait for routine imaging turnaround.

Take the history from the child as far as age allows, and from the carer separately. Use open questions, a calm face, and avoid leading the child. Record exact words used.

• Onset and course. When did the discharge or bleeding start, how often, how much (spots on underwear, soaking pads), what colour, is there odour, clots, tissue, or foreign material?
• Associated symptoms. Itching, soreness, dysuria (may be vulvovaginitis rather than urinary infection), pain, constipation, perineal pruritus at night (threadworm), recent diarrhoea or vulvitis after a course of antibiotics.
• Irritants and hygiene. Bubble baths, shampoos, wipes, tight or nylon underwear, nappies or pull-ups, swimming, fragranced products, front-to-back wiping habits.
• Pubertal development. Any breast budding (symmetry? tenderness?), pubic hair, growth spurt, body odour, vaginal bleeding; age of the mother's menarche and any family history of early puberty.
• Medications and exposure. Topical oestrogen or steroid creams, contraceptive or hormone use in the household (creams can be transferred), medicines, supplements.
• Safeguarding domains. Behavioural changes, sexualised behaviour inappropriate to age, sleep disturbance, soiling, encopresis, disclosures, supervision, digital access, contact with known offenders, family stress, and whether the carer is calm and consistent or evasive. Do not cross-examine; document verbatim and refer.
• Past history. Previous episodes, hospital admissions, immunocompromise or diabetes (affecting candida risk), chronic illness.
• Development. Milestones, growth trajectory, nutrition, pubertal staging against age.

The most useful single clue separating causes is persistence: non-specific vulvovaginitis fluctuates; a foreign body or polyp usually produces a steady or recurrent unilateral discharge; precocious puberty produces cyclical or repeated small bleeds alongside breast development and accelerated height velocity.

Examine gently, with a parent present, and only to the extent required. Internal examination of a prepubertal girl in the clinic is not appropriate and is not tolerated.

• General and growth. Height and weight (with centiles), blood pressure if indicated, signs of puberty (Tanner staging of breast and pubic hair), virilisation, café-au-lait patches, neurocutaneous signs.
• Abdomen. Tenderness, masses, hepatosplenomegaly.
• Perineum (external only). In frog-leg or knee-chest position; inspect labia, posterior fourchette, hymen, clitoris, urethral meatus, perianal area for redness, discharge, erosions, fissures, excoriation, lichenoid change, foreign body, polyps or masses.
• Swabs. A sterile cotton-wool swab from the vaginal introitus (low, external) for microscopy, culture, and, if STI is suspected, nucleic acid amplification. Do not insert swabs into the vagina.
• Neurological and visual when precocious puberty is considered: fundi, visual fields, cranial nerves, signs of raised intracranial pressure.
• Skin and skeleton. Pigmented lesions, bone deformity or pain in McCune-Albright syndrome.

If the child is distressed or the examination cannot be completed safely, stop and proceed under general anaesthesia rather than restrain.

Think of investigations in rising order of invasiveness, and tie each one to what it answers.

1. Urine. Dipstick and, when dysuria is present, culture: this distinguishes cystitis and urethritis from vulvovaginitis.
2. Introital swab. Microscopy and culture (aerobes, anaerobes, Candida, STI testing where indicated). Manage on culture: antibiotics only for pure or predominant growth of a recognised pathogen.^[2]
3. Pelvic ultrasound (transabdominal). First-line imaging when bleeding, persistent discharge, a mass is suspected or when pubertal precocity is considered. It assesses uterine size and shape, ovarian cysts or tumours, retained foreign objects and, indirectly, any corpus:cervix ratio change suggestive of puberty. Its role is imaging, not proof: in one series of 54 girls with preoperative ultrasound and confirmed findings at vaginoscopy, only 20.4% of scans were abnormal, and three-quarters of abnormal ultrasounds in the bleeding group were later diagnosed as central precocious puberty rather than tumour. A normal scan (79.6%) does not exclude a small foreign body, especially organic material such as toilet paper. For foreign bodies specifically, reported sensitivities vary widely (roughly one third to 90%) depending on object size and technique. Use ultrasound to look, never to rule out.^[1]
4. Hormonal studies (only when puberty is in question). Basal LH using an ultrasensitive assay, oestradiol, and, depending on presentation, FSH, testosterone/DHEAS and 17-hydroxyprogesterone. Advanced bone age supports an oestrogen-driven process; delayed bone age with precocious puberty raises hypothyroidism (van Wyk-Grumbach).
5. GnRH stimulation test. Used to separate central from peripheral precocious puberty when basal LH is equivocal. In central puberty, LH rises into the pubertal range and oestradiol is high; in peripheral causes, LH remains in the prepubertal range.
6. Brain imaging. MRI of the brain and pituitary is not routinely performed in girls aged 6 to 8, or boys aged 8 to 9, who have precocious puberty but no central nervous system symptoms; pathogenic intracranial lesions are uncommon in that group.^[3] MRI is indicated with onset before age 6, neurological signs, very rapid progression, elevated IGF-1 or other concern.
7. Genetic testing. Not routine. Consider MKRN3 sequencing and other familial precocious puberty genes for a family history via shared decision-making.^[3]
8. Vaginoscopy under general anaesthesia. The investigation that diagnoses or excludes a foreign body, mass, trauma or anatomical abnormality, and allows biopsy. In the series above, vaginoscopy under anaesthesia established a diagnosis in about 42% of bleeding presentations and 47% of discharge presentations, with no intra- or postoperative complications.^[1] The number needed to investigate to detect a malignant cause was 43.^[1] Before it is booked, recognise that the procedure uses scarce theatre time; book promptly when red flags exist but avoid over-investigating mild, short-lived discharges.

The correct local sequence must always be adapted to the child and to available expertise. What matters is that no girl with persistent bleeding is discharged without either a clear diagnosis or a planned examination under anaesthesia.

The modern approach, set out in the Endocrine Society clinical practice guideline published in 2026, is more restrained than older practice.^[3]

• Observe first when appropriate. In girls with breast development (thelarche, Tanner stage 2) between ages 7.0 and 8.0, watchful waiting with periodic physical examination every 4 to 6 months is suggested rather than immediate laboratory or imaging investigation. Girls with breast development before age 7 should first be observed for 4 to 6 months to distinguish unsustained or slowly progressive puberty from rapidly progressive puberty.^[3]
• Then evaluate if progression. Hormonal evaluation, when performed, should start with an ultrasensitive basal LH rather than routine GnRH stimulation testing for every patient.^[3]
• Imaging by risk. Brain MRI is not routinely used in girls aged 6 to 8 (or boys 8 to 9) without neurological symptoms, because pathologic intracranial findings are uncommon in that group; image when onset is earlier, progression is rapid, or neurological signs exist.^[3]
• Genetics sparingly. Routine genetic testing is not recommended; consider MKRN3 sequencing in familial central precocious puberty via shared decision-making.^[3]
• Peripheral pathway. A girl with peripheral puberty needs cause-directed investigation: pelvic ultrasound for ovarian cysts/tumours, 17-hydroxyprogesterone (congenital adrenal hyperplasia), adrenal androgens, thyroid function, and, if needed, imaging for adrenal or ovarian tumours.

• Central precocious puberty. GnRH agonists suppress the axis and are effective. The strongest evidence for increasing adult height is in early-onset central precocious puberty (onset before age 6 in girls); more recent guidance emphasises that girls with slowly progressive puberty or onset close to normal pubertal age are less likely to benefit.^[4][3] Treat those who need it (rapid progression, significant bone-age advancement, psychological burden, or young age). Start with the formulation anticipated for long-term use, such as a longer-acting preparation, rather than routinely beginning with monthly injections.^[3] Do not add growth hormone routinely to increase height.^[3] Monitor by clinical assessment: growth velocity, Tanner stage and periodic bone age. Routine LH or sex steroid testing is not needed; reserve biochemical testing for suspected treatment failure.^[3] Plan to stop treatment around chronological age 10 to 11 (girls) and/or bone age 11 to 12, not routinely continuing beyond.^[3] Psychological support and counselling for the child and family matter throughout.
• Peripheral precocious puberty. GnRH agonists do not work. Management is cause-directed: remove exogenous oestrogen source, surgical removal of an ovarian or adrenal tumour, glucocorticoid replacement for congenital adrenal hyperplasia, treatment of hypothyroidism. Specialised centres manage McCune-Albright-related autonomous cysts; aromatase inhibitors and antiandrogens have been used and are not routine standard. Long-term follow-up is needed because of the tumour risk in some syndromes.
• Practical dosing. Specific drug doses, routes and depot intervals vary by product and region; follow the current BNFc/NICE-approved paediatric endocrinology protocols and local formulary, and involve the treating endocrinologist. No dose in this page should be taken as absolute.

• Explain that bleeding in a prepubertal girl is abnormal and that investigation is safety-led.
• Start a vulvovaginitis hygiene plan and avoid irritants.
• Arrange safeguarding consultation immediately if abuse, STI-pathogen growth, genital injury or concerning behaviour exists.
• Book urgent imaging or vaginoscopy for red flags.
• Refer suspected precocious puberty to paediatric endocrinology, with baseline measurements already taken (height, weight, Tanner, growth velocity if available).

• Vulvovaginitis. Hygiene counselling, sitz baths, barrier creams. Treat a named pathogen with targeted antibiotics. Treat threadworm. Check for anatomical or dermatological causes if recurrence.
• Foreign body. Examination under general anaesthesia and vaginoscopy; remove all fragments, inspect for trauma and fistula, take directed biopsies if a mass is seen.
• Precocious puberty. Endocrinology-led; GnRH agonist if indicated; surgery or medical therapy for peripheral causes; annual or more frequent follow-up of growth and bone age.
• Malignancy. Multidisciplinary team: paediatric oncology, surgery, radiology; biopsy-first where appropriate; avoid unnecessary delay.
• Safeguarding. Child-centred, forensically informed, multidisciplinary; follow WHO 2017 recommendations on post-rape care and on minimizing distress during history-taking and examination. Prioritise safety, offer choices, respect autonomy.^[5]

• Recheck that symptoms have settled and there is no recurrence.
• Document growth chart and pubertal status at each visit.
• In central precocious puberty, reassess the need to continue or stop GnRH agonist at the age/bone-age thresholds above.
• Continue long-term follow-up after foreign-body removal or tumour treatment; missed fragments recur.
• Offer families written information and a named contact.

• Neonates. A small amount of blood-stained or mucous discharge in the first week of life is physiological withdrawal bleeding. It is self-limited. No investigation or treatment is needed if it stops within days and the baby is otherwise well; if it persists beyond the first week or is heavy, investigate.
• Adolescents who have just started puberty. Physiological leucorrhoea and premenarchal hormonal fluctuations can produce discharge. Differentiate from infection or retained products.
• Children with disability, chronic illness or communication difficulties. They may present late, with pain, screaming at micturition or behavioural change rather than a complaint. Have a low threshold for examination under anaesthesia when symptoms are unexplained.
• Immunocompromise. Candida and other opportunistic infection become more likely; treat the child and the underlying condition.
• Low-resource settings. Vaginoscopy, pelvic ultrasound, bone age and GnRH stimulation may not be available. In that case: treat non-specific vulvovaginitis with hygiene and watchful waiting; use a presumptive pure-growth antibiotic policy only when a pathogen is cultured or clinical infection is clear; refer children with bleeding, mass, red flags or suspected precocity to the highest level of care; and when a foreign body is strongly suspected, examination under anaesthesia with a speculum or hysteroscope by an experienced clinician is safer than repeated empirical antibiotics.
• Safeguarding and consent. Always follow local child-protection policy and the named safeguarding lead. Consent for examination under anaesthesia rests with the carer with parental responsibility, but if abuse is suspected the child's safety overrides confidentiality. WHO's 2017 guidance focuses on trauma-informed, child-centred post-abuse care.^[5]

• Assuming prepubertal discharge is normal; after the neonatal period it is not.
• Forgetting the first-week physiological withdrawal bleed and over-investigating a well neonate.
• Prescribing antibiotics empirically for non-specific vulvovaginitis. Evidence favours targeted treatment after culture.^[2]
• Using an ultrasound to rule out a foreign body. A normal scan does not exclude small organic material.^[1]
• Repeating swabs without acting on them, or treating commensals as pathogens.
• Performing internal examinations in the clinic on a prepubertal girl.
• Starting a GnRH agonist for peripheral precocious puberty, where it cannot work.
• Imaging every girl aged 6 to 8 with precocious puberty with MRI by default; modern guidance reserves it.^[3]
• Continuing GnRH agonist treatment past age 10 to 11 or bone age 11 to 12 without a clear reason.^[3]
• Adding growth hormone routinely to increase height.^[3]
• Missing a genital mass in a bleeding toddler by assuming a minor trauma.
• Not documenting safeguarding concerns accurately and promptly.

The recommendations in this page draw on the following named guidelines and consensus documents, and the reader should note that editions, age cut-offs and treatment policies vary by country and by era:

• Endocrine Society Clinical Practice Guideline: Central Precocious Puberty (Latronico et al, Journal of Clinical Endocrinology and Metabolism, 2026).^[3]
• ESPE-LWPES Consensus Statement on the use of gonadotropin-releasing hormone analogs in children (Carel et al, Pediatrics, 2009).^[4]
• WHO clinical guidelines: Responding to children and adolescents who have been sexually abused (2017).^[5]
• For vulvovaginitis and management of children with genital symptoms, UK practice references national British guidance on sexually transmitted infections in children and young people, RCOG service-level and archived vulval guidance (Green-top Guideline No. 58) and, in North America, ACOG and AAP resources for paediatric and adolescent gynaecology; local safeguarding and child-protection frameworks apply in all regions. No single international guideline covers childhood vaginal discharge end-to-end, which is why this page follows the evidence base summarised above rather than one organisation.
• NICE does not currently publish a dedicated clinical guideline on precocious puberty; UK practice uses regional NHS pathways, the BNFC for medicines, and, for heavy or abnormal bleeding, relevant NICE guidance on menstrual disorders and paediatric care. ESPE and Endocrine Society guidance are the principal sources for puberty; WHO for post-abuse care.

Child sexual abuse and neglect; congenital adrenal hyperplasia; disorders of sex development; hyperthyroidism and hypothyroidism; McCune-Albright syndrome; neonatal withdrawal bleeding; pelvic ultrasound in children; paediatric resuscitation and the sick child; vulvovaginitis and vaginal discharge (adult); vulvar and vaginal tumours.

• In prepubertal girls, vaginal bleeding is always abnormal after the neonatal period, and persistent discharge usually is too.
• Non-specific vulvovaginitis, irritants and poor hygiene are the commonest causes; antibiotics are reserved for pure or predominant growth of a recognised pathogen.
• Foreign bodies are common, under-diagnosed on ultrasound, and treated by examination under anaesthesia and vaginoscopy.
• Abuse must be considered for persistent or recurrent discharge, genital injury, or organisms associated with sexual transmission, following WHO 2017 trauma-informed principles.
• Neonatal withdrawal bleeding in the first week of life is physiological and self-limited.
• Precocious puberty is divided into central (brain-driven, GnRH-dependent) and peripheral (ovarian/adrenal/iatrogenic).
• Central precocious puberty usually presents at under age 8; modern Endocrine Society 2026 guidance favours watchful waiting in many girls with onset at 7 to 8, and early treatment where onset is under 6.
• Peripheral causes require cause-directed treatment, not GnRH agonists.
• Brain MRI is not routine in girls aged 6 to 8 with precocious puberty without neurological symptoms.
• GnRH agonist treatment, when indicated, is monitored clinically and stopped around age 10 to 11 or bone age 11 to 12.